Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPGM | P07738 | 3/20 | 0.65 |
| ▸ | EIF4E | P06730 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24348944 | 0.89 | BPGM (0.68) | BPGMEIF4EMEN1KMT2AGAA | |
| SCHEMBL24348540 | 0.87 | BPGM (0.65) | BPGMEIF4EMEN1KMT2AGAA | |
| SCHEMBL24348948 | 0.87 | BPGM (0.73) | BPGMMEN1KMT2AGAAXDH | |
| SCHEMBL24271792 | 0.86 | BPGM (0.57) | BPGMEIF4EMEN1KMT2AGAA | |
| SCHEMBL24348943 | 0.85 | BPGM (0.67) | BPGMMEN1KMT2AGAAXDH | |
| SCHEMBL24271967 | 0.83 | BPGM (0.65) | BPGMEIF4EMEN1KMT2AGAA | |
| SCHEMBL24272004 | 0.82 | BPGM (0.57) | BPGMEIF4EMEN1KMT2AGAA | |
| SCHEMBL24348548 | 0.82 | BPGM (0.77) | BPGMMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL24271879 | 0.81 | BPGM (0.66) | BPGMEIF4EMEN1KMT2AGAA | |
| SCHEMBL24348946 | 0.81 | BPGM (0.60) | BPGMMEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056449-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, HBG1 | BPGM 1/4885EIF4E 3508/4885MEN1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.